Literature DB >> 6420543

Blood vessel uptake and metabolism of organic nitrates in the rat.

H L Fung, S C Sutton, A Kamiya.   

Abstract

Recent reports have suggested that the unusual pharmacokinetics observed for nitroglycerin (NTG) and isosorbide dinitrate (ISDN) may be partially explained by extensive uptake and/or metabolism of these drugs by vascular and other extrahepatic tissues. Using the rat as an animal model, this hypothesis was examined by in vivo intravessel NTG and [14C]ISDN infusion and injection into various vessel segments, viz. the femoral vein, inferior vena cava [IVC: lower, middle and upper) and the aorta. NTG and [14C]ISDN concentrations were determined in these blood vessels and in plasma. Blood vessel segments nearest the input site had the greatest amounts of nitrate, whereas segments further away from the input site had progressively less nitrate, with the exception of aorta, which appeared to take up NTG less extensively, on a per weight of vessel basis, than the IVC. Blood vessel NTG concentrations (nanogram per gram) were generally higher (10-fold) and declined about twice as slowly as NTG plasma concentrations (nanograms per milliliter). [14C]NTG and [14C]ISDN were also incubated with cofactors in IVC, aorta, abdominal muscle, lung and liver. The amounts of nitrate metabolites formed from parent drug were larger in each extrahepatic tissue incubation than in the controls (P less than .05). The results are consistent with the hypothesis that vascular and other extrahepatic tissues can take up and/or metabolize organic nitrates. The data appear to provide a partial explanation for the large systemic clearance seen with nitrates and appear consistent with existing mechanistic hypotheses for the vascular action of these compounds.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6420543

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

Review 1.  Anatomical-physiological approaches in pharmacokinetics and pharmacodynamics.

Authors:  L E Mather
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure.

Authors:  A Meissner; S Petersenn; H T Heidemann; U Osterkamp; R Simon; H M Schulte
Journal:  Klin Wochenschr       Date:  1991-03-18

Review 3.  Is there counter-current exchange of drugs in limbs after percutaneous absorption?

Authors:  J F Hecker
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

4.  Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin.

Authors:  E Nakashima; P K Noonan; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1987-08

5.  Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate.

Authors:  F Wagner; F Siefert; D Trenk; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Endothelium- and sydnonimine-induced responses of native and cultured aortic smooth muscle cells are not impaired by nitroglycerin tolerance.

Authors:  A Mülsch; R Busse; I Winter; E Bassenge
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

7.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 8.  Mechanisms of action of nitrates.

Authors:  K E Torfgård; J Ahlner
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 9.  Nitrate tolerance. A review of the evidence.

Authors:  J T Flaherty
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

10.  Variable glyceryl dinitrate formation following infusions of glyceryl trinitrate at different vascular sites in the rat.

Authors:  E Nakashima; D T Lau; L Z Benet
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.